Breezebio

BreezeBio (formerly GenEdit) is a South San Francisco genetic-medicine company developing precision-delivered nucleic acid therapies for autoimmune disease and oncology. Its proprietary NanoGalaxy platform uses non-lipid, hydrophilic polymer nanoparticles of tunable size, charge, and composition to selectively deliver DNA, RNA, and ribonucleoprotein payloads to specific tissues and cell types beyond the liver — including immune cells and targets in the heart, lung, and central nervous system. The company is advancing an internal therapeutic pipeline led by BRZ-101, which aims to restore immune tolerance in type 1 diabetes, and in February 2026 closed a $60M Series B backed by DCVC Bio, Sequoia Capital, and other investors. BreezeBio is a research-stage biopharmaceutical company and does not currently publish a public developer API, SDKs, or API documentation; this profile tracks its corporate and identity surface within the API Evangelist network.

Breezebio is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Genetic Medicine, Drug Delivery, and Therapeutics.

Breezebio’s developer surface includes engineering blog, support, and 3 more developer resources.

🌐 Visit website 📡 Source on GitHub

13.0/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiotechnologyGenetic MedicineDrug DeliveryTherapeuticsLife SciencesNanoparticlesHealthcare

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 13.0/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 1.3 / 20

Commercial Clarity 4.2 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/breezebio: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Resources

Operate 1

Status, limits, changes, and where to get help

Support

Support

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

TermsOfService

TermsOfService

Company 2

The organization behind the API

Website

Website

Blog

Blog

Source (apis.yml)

aid: breezebio
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/breezebio.png
name: Breezebio
description: BreezeBio (formerly GenEdit) is a South San Francisco genetic-medicine company developing precision-delivered
  nucleic acid therapies for autoimmune disease and oncology. Its proprietary NanoGalaxy platform uses non-lipid, hydrophilic
  polymer nanoparticles of tunable size, charge, and composition to selectively deliver DNA, RNA, and ribonucleoprotein payloads
  to specific tissues and cell types beyond the liver — including immune cells and targets in the heart, lung, and central
  nervous system. The company is advancing an internal therapeutic pipeline led by BRZ-101, which aims to restore immune tolerance
  in type 1 diabetes, and in February 2026 closed a $60M Series B backed by DCVC Bio, Sequoia Capital, and other investors.
  BreezeBio is a research-stage biopharmaceutical company and does not currently publish a public developer API, SDKs, or
  API documentation; this profile tracks its corporate and identity surface within the API Evangelist network.
url: https://raw.githubusercontent.com/api-evangelist/breezebio/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- dcvc
- sequoia-capital
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Biotechnology
- Genetic Medicine
- Drug Delivery
- Therapeutics
- Life Sciences
- Nanoparticles
- Healthcare
apis: []
common:
- type: Website
  url: https://breezebio.com/
- type: Blog
  url: https://breezebio.com/news/
- type: Support
  url: https://breezebio.com/contact/
- type: PrivacyPolicy
  url: https://breezebio.com/legal/privacy-policy/
- type: TermsOfService
  url: https://breezebio.com/legal/terms-of-use/
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence